Tenaya Therapeutics shares surge 12.48% intraday after positive MyPEAK-1 data and DSMB support for dose expansion in lead gene therapy programs.

Tenaya Therapeutics surged 12.48% intraday after reporting positive clinical data from its gene therapy programs and improved financials. The company highlighted durable, dose-dependent MyBP-C protein increases in TN-201’s MyPEAK-1 trial, with Cohort 1 showing deeper reductions in hypertrophy and manageable safety profiles. TN-401’s RIDGE-1 trial completed Cohort 2 dosing, while Cohort 1 data are expected by year-end. Both programs received favorable Data Safety Monitoring Board (DSMB) recommendations for dose expansion. Financially, Q3 net loss narrowed 21% to $20.3M, with $56.3M in cash supporting operations into late 2026. Despite a clinical hold on MyPEAK-1 for protocol amendments, management emphasized no impact on data timelines. The stock’s rally reflects optimism over therapeutic progress and cost discipline, with investors focusing on clinical milestones and regulatory pathway clarity.